New drug combo shows promise in advanced lung cancer trial
NCT ID NCT03581487
First seen Nov 06, 2025 · Last updated May 01, 2026 · Updated 19 times
Summary
This study tested a mix of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (selumetinib) in 40 people with advanced non-small cell lung cancer that had returned. The goal was to find the safest dose and see if the combination could shrink tumors or slow cancer growth. While the approach aims to control the disease, it is not a cure, and ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.